Kidney Week

Abstract: TH-PO1148

Mild COVID-19 Infection Does Not Affect CKD Indices

Session Information

• COVID-19
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

• 000 Coronavirus (COVID-19)

Authors

• Angel-Korman, Avital, Assuta Ashdod University Hospital, Ashdod, South, Israel

Avital Angel-Korman, MD

• Leiba, Adi, Assuta Ashdod University Hospital, Ashdod, South, Israel

Adi Leiba, MD

• Brosh-Nissimov, Tal, Assuta Ashdod University Hospital, Ashdod, South, Israel

Tal Brosh-Nissimov, MD

• Mayer, Ori, Tel Aviv University Faculty of Medicine, Tel Aviv, Tel Aviv, Israel

Ori Mayer, MSc, PhD

Background

COVID-19 in hospitalized patients has been implicated in the deterioration of several indices associated with chronic kidney disease (CKD), including new onset hypertension, and worsening of proteinuria and kidney function. Nevertheless, the influence of COVID-19 on these parameters in patients with CKD has not been fully elucidated.
We aimed to study the effect of COVID-19 on blood pressure (BP), proteinuria, and eGFR in a community-based cohort of patients with CKD

Methods

A retrospective cohort study using data obtained from Maccabi Healthcare Services (MHS) during COVID-19 pandemic. MHS, is a nationwide payer-provider healthcare system, with an extended database including laboratory information, vital signs documentation and a well validated CKD registry. Included in the study were all adults (over 18 years of age) with CKD stages I-V insured in MHS, who had a first documented mild-moderate laboratory-confirmed COVID-19, not requiring hospitalization. All reported BP clinic measurements within one year prior to and following COVID-19, were averaged, and so were urine albumin and serum creatinine (sCr) measurements

Results

43,875 patients were registered as having CKD in MHS and had a documented 1^st COVID-19 infection between 2020-2022. Mean age was 69.3 (±12.9) years and 21,775 (49.6%) were males. Following COVID-19, systolic BP was 1 mmHg lower and diastolic BP was 0.6 lower compared with pre-COVID-19 values (P-value 0.03 and 0.004, respectively). 8918 patients had at least 2 documented urine albumin to creatinine ratio (UACR) measurements. The mean UACR was 64mg (±233) before and 93mg (±322) after COVID-19, accounting for an absolute difference of 29mg (±294), p<0.001. Patients with baseline albuminuria >300mg had a mean decrease in albumin level of 263mg (+676) following COVID-19. In 37,923 patients who were tested for sCr, eGFR was 73.2ml/min (±19.8) and 72.2ml/min (±20) before and after COVID-19, respectively - an absolute difference of 1ml/min (±8.9), p<0.001.
Adjustment for changes in medications including ACE INH, ARBs, diuretics MRAs and SGLT2 inhibitors did not significantly affect the results

Conclusion

Although some differences in CKD indices were statistically significant given the large cohort size, none were clinically significant. Mild-moderate COVID-19 did not affect indices of CKD and is therefore unlikely to be associated with CKD progression

Funding

• Private Foundation Support